key: cord-0766151-4jgcbgxg
authors: Finsterer, Josef; Almas, Talal
title: Guillain‐Barré syndrome is immunogenic in SARS‐CoV‐2 infected
date: 2021-09-08
journal: J Med Virol
DOI: 10.1002/jmv.27314
sha: 456fafe283baa3ff230b05accc7823a67080bf2e
doc_id: 766151
cord_uid: 4jgcbgxg

nan

To the Editor, With interest, we read the article by Khan 1 Three patients were classified as acute, inflammatory, demyelinating polyneuropathy (AIDP) and one each as acute, motor, axonal neuropathy (AMAN) respectively acute, motor, and sensory, axonal neuropathy (AMSAN). 1 It was concluded that "in a few cases where the symptoms of COVID-19 and GBS occur concurrently (corresponding to the viremic phase), a separate, para-infectious pathogenesis needs to be thought of". 1 The study is appealing but prompts comments and concerns.

There is currently no evidence that SACAG is infectious. In a recent review of 300 patients with SACAG, of whom 68 underwent investigations for virus-RNA in the CSF, virus-RNA was detected only in a single patient. 1 A second SACAG patient has been recently reported in whom CSF tested positive for the virus. 2 4 In particular, interleukin-8 has been found to be elevated in the CSF of SACAG patients. 4 In addition to interleukin-8, interleukin-6 was elevated in the serum and CSF in the acute phase of SACAG patients. 5 At the 4 months follow-up, only interleukin-8 had remained elevated in the serum. 6 A further argument is that certain HLA alleles known to be associated with GBS, such as class-I (HLA-A33) and class-II alleles (DRB1*03:01 and DQB1*05:01), have also been detected in SACAG patients, further invoking an underlying immunogenic etiology. 4 Another indication for an immune reaction is that CSF protein is usually elevated in the absence of pleocytosis. 6 Overall, there are more arguments in favor of the immunogenic pathophysiology of SACAG than in favor of the infectious patho-

COVID-19-associated Guillain-Barre syndrome: postinfectious alone or neuroinvasive too

First report of SARS-CoV-2 detection in cerebrospinal fluid in a child with Guillain-Barré syndrome

Guillain-Barre syndrome in 220 patients with COVID-19

HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome

Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients

Axonal Guillain-Barre syndrome associated with SARS-CoV-2 infection in a child